Advertisement
U.S. markets open in 3 hours 27 minutes

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.7500+0.0400 (+2.34%)
At close: 04:00PM EDT
1.7590 +0.01 (+0.51%)
After hours: 06:11PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.7100
Open1.6900
Bid1.6800 x 1000
Ask1.6700 x 2200
Day's Range1.6900 - 1.7500
52 Week Range1.5600 - 2.1600
Volume7,222
Avg. Volume27,400
Market Cap25.377M
Beta (5Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-0.3700
Earnings DateApr 22, 2024 - Apr 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ABIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ARCA biopharma, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/27/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    ARCA biopharma Announces 2023 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2023 financial results and provided a corporate update. In April 2022, the Board of Directors establi

  • Simply Wall St.

    We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    ARCA biopharma Announces Third Quarter 2023 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Dir